Endocrinology and Metabolism

Tae Nyun Kim (Kim TN)

3 Articles

Co-Culture of α TC-6 Cells and β TC-1 Cells: Morphology and Function: Sung Man Kim, Eun Ju Lee, Hye Sook Jung, Na Han, You Jeong Kim, Tae Kyoon Kim, Tae Nyun Kim, Min Jeong Kwon, Soon Hee Lee, Jeong Hyun Park, Byoung Doo Rhee, Mi-Kyung Kim; Endocrinol Metab. 2015;30(1):92-97. Published online March 27, 2015; DOI: https://doi.org/10.3803/EnM.2015.30.1.92

5,162 View
74 Download
4 Web of Science
4 Crossref

Background

In vitro experiments using only β-cell lines instead of islets are limited because pancreatic islets are composed of four different types of endocrine cells. Several recent studies have focused on cellular interactions among these cell types, especially α- and β-cells. Because islet isolation needs time and experience, we tested a simple co-culture system with α- and β-cells. Their morphology and function were assessed by comparison to each single cell culture and pancreatic islets.

Methods

α TC-6 cells and β TC-1 cells were maintained in Dulbecco's Minimal Essential Medium containing 5 mM glucose and 10% fetal bovine serum. Cells were mixed at a 1:1 ratio (5×10⁵) in 6-well plates and cultured for 24, 48, and 72 hours. After culture, cells were used for insulin and glucagon immunoassays and tested for glucose-stimulated insulin secretion (GSIS).

Results

α TC-6 and β TC-1 cells became condensed by 24 hours and were more strongly compacted after 48 hours. β TC-1 cells showed both β-β and β-α cell contacts. GSIS increased with increasing glucose concentration in co-cultured cells, which showed lower secreted insulin levels than β TC-1 cells alone. The increase in the secreted insulin/insulin content ratio was significantly lower for co-cultured cells than for β-cells alone (P=0.04). Compared to islets, the α-/β-cell co-culture showed a higher ratio of GSIS to insulin content, but the difference was not statistically significant (P=0.09).

Conclusion

α TC-6 and β TC-1 cells in the co-culture system showed cell-to-cell contacts and a similar stimulated insulin secretion pattern to islets. The co-culture system may be used to better mimic pancreatic islets in in vitro assessments.

Citations

Citations to this article as recorded by

Pancreatic islet cells in microfluidic-spun hydrogel microfibers for the treatment of diabetes
Zhikun Huan, Jingbo Li, Jiahui Guo, Yunru Yu, Ling Li
Acta Biomaterialia.2024;[Epub] CrossRef
Recent advances in the design of implantable insulin secreting heterocellular islet organoids
M. Birgul Akolpoglu, Yasemin Inceoglu, Ugur Bozuyuk, Ana Rita Sousa, Mariana B. Oliveira, João F. Mano, Seda Kizilel
Biomaterials.2021; 269: 120627. CrossRef
Pancreatic β Cells Inhibit Glucagon Secretion from α Cells: An In Vitro Demonstration of α–β Cell Interaction
Wenqian Gu, Camilla Christine Bundgaard Anker, Christine Bodelund Christiansen, Tilo Moede, Per-Olof Berggren, Kjeld Hermansen, Søren Gregersen, Per Bendix Jeppesen
Nutrients.2021; 13(7): 2281. CrossRef
The Role of Pancreatic Alpha Cells and Endothelial Cells in the Reduction of Oxidative Stress in Pseudoislets
Fredrik C. Wieland, Mireille M.J.P.E. Sthijns, Thomas Geuens, Clemens A. van Blitterswijk, Vanessa L.S. LaPointe
Frontiers in Bioengineering and Biotechnology.2021;[Epub] CrossRef

Obesity and Metabolism
A1c Variability Can Predict Coronary Artery Disease in Patients with Type 2 Diabetes with Mean A1c Levels Greater than 7: Eun Ju Lee, You Jeong Kim, Tae Nyun Kim, Tae Ik Kim, Won Kee Lee, Mi-Kyung Kim, Jeong Hyun Park, Byoung Doo Rhee; Endocrinol Metab. 2013;28(2):125-132. Published online June 18, 2013; DOI: https://doi.org/10.3803/EnM.2013.28.2.125

4,016 View
28 Download
12 Web of Science
16 Crossref

Abstract PDF PubReader

Background

Recent studies suggested that the association of acute glucose variability and diabetic complications was not consistent, and that A1c variability representing long term glucose fluctuation may be related to coronary atherosclerosis in patients with type 1 diabetes. In this study, we attempt to determine whether or not A1c variability can predict coronary artery disease (CAD) in patients with type 2 diabetes.

Methods

We reviewed data of patients with type 2 diabetes who had undergone coronary angiography (CAG) and had been followed up with for 5 years. The intrapersonal standard deviation (SD) of serially-measured A1c levels adjusted by the different number of assessments among patients (adj-A1c-SD) was considered to be a measure of the variability of A1c.

Results

Among the 269 patients, 121 of them had type 2 diabetes with CAD. In patients with A1c ≥7%, the mean A1c levels and A1c levels at the time of CAG among the three groups were significantly different. The ratio of patients with CAD was the highest in the high adj-A1c-SD group and the lowest in the low adj-A1c-SD group (P=0.017). In multiple regression analysis, adj-A1c-SD was an independent predictor for CAD in subjects with A1c ≥7% (odds ratio, 2.140; P=0.036).

Conclusion

Patients with higher A1c variability for several years showed higher mean A1c levels. A1c variability can be an independent predictor for CAD as seen in angiographs of patients with type 2 diabetes with mean A1c levels over 7%.

Citations

Citations to this article as recorded by

Assessment of fasting plasma glucose, insulin, insulin resistance and glycated haemoglobin as markers of glycemic control in apparently healthy older adults in Nnewi
Emmanuel Chukwuemeka Ogbodo, Christian Ejike Onah, Akuma Kalu Amah, Chinenye Stellamaris Okeke, Maryrose Oluchukwu Obiorah, Alozie Ogwuegbu Okezie, Romanus Ogai Ogalagu, Joy Chidinma Iwuji, Raphael Emmanuel Mbam, Samuel Chukwuemeka Meludu
Indian Journal of Forensic and Community Medicine.2024; 11(2): 49. CrossRef
Intermediate- and long-term associations between air pollution and ambient temperature and glycated hemoglobin levels in women of child bearing age
Mike Z. He, Itai Kloog, Allan C. Just, Iván Gutiérrez-Avila, Elena Colicino, Martha M. Téllez-Rojo, María Luisa Pizano-Zárate, Marcela Tamayo-Ortiz, Alejandra Cantoral, Diana C. Soria-Contreras, Andrea A. Baccarelli, Robert O. Wright, Maayan Yitshak-Sade
Environment International.2022; 165: 107298. CrossRef
Correlation between HbA1c and Triglyceride Level with Coronary Stenosis Degree in Type 2 Diabetes Mellitus with Coronary Heart Disease
Laily Adninta, Indranila Samsuria, Edward Kurnia Setiawan Limijadi
Open Access Macedonian Journal of Medical Sciences.2022; 10(B): 944. CrossRef
Long-Term Glycemic Variability and Vascular Complications in Type 2 Diabetes: Post Hoc Analysis of the FIELD Study
Emma S Scott, Andrzej S Januszewski, Rachel O’Connell, Gregory Fulcher, Russell Scott, Antero Kesaniemi, Linda Wu, Stephen Colagiuri, Anthony Keech, Alicia J Jenkins
The Journal of Clinical Endocrinology & Metabolism.2020; 105(10): e3638. CrossRef
How Continuity in Service Impacts Process Variability: Evidence from a Primary Care Setting
Vishal Ahuja, Carlos Alvarez, Bradley R. Staats
SSRN Electronic Journal .2019;[Epub] CrossRef
Association of hemoglobin A1c variability and the incidence of heart failure with preserved ejection fraction in patients with type 2 diabetes mellitus and arterial hypertension
Jun Gu, Yu-Qi Fan, Jun-Feng Zhang, Chang-Qian Wang
Hellenic Journal of Cardiology.2018; 59(2): 91. CrossRef
Prognostic impact of HbA1c variability on long-term outcomes in patients with heart failure and type 2 diabetes mellitus
Jun Gu, Jian-an Pan, Yu-qi Fan, Hui-li Zhang, Jun-feng Zhang, Chang-qian Wang
Cardiovascular Diabetology.2018;[Epub] CrossRef
Cardiovascular Autonomic Neuropathy Predicts Higher HbA1c Variability in Subjects with Type 2 Diabetes Mellitus
Yeoree Yang, Eun-Young Lee, Jae-Hyoung Cho, Yong-Moon Park, Seung-Hyun Ko, Kun-Ho Yoon, Moo-Il Kang, Bong-Yun Cha, Seung-Hwan Lee
Diabetes & Metabolism Journal.2018; 42(6): 496. CrossRef
Glycated hemoglobin level is an independent predictor of major adverse cardiac events after nonfatal acute myocardial infarction in nondiabetic patients
Chin-Lan Chen, David H.-T. Yen, Chin-Sheng Lin, Shih-Hung Tsai, Sy-Jou Chen, Wayne H.-H. Sheu, Chin-Wang Hsu
Medicine.2017; 96(18): e6743. CrossRef
Randomized, Open-Label, Parallel Group Study to Evaluate the Effect of Internet-Based Glucose Management System on Subjects with Diabetes in China
Hun-Sung Kim, Chenglin Sun, So Jung Yang, Lin Sun, Fei Li, In Young Choi, Jae-Hyoung Cho, Guixia Wang, Kun-Ho Yoon
Telemedicine and e-Health.2016; 22(8): 666. CrossRef
Association between hemoglobin A1c variability and subclinical coronary atherosclerosis in subjects with type 2 diabetes
Hae Kyung Yang, Borami Kang, Seung-Hwan Lee, Kun-Ho Yoon, Byung-Hee Hwang, Kiyuk Chang, Kyungdo Han, Gunseog Kang, Jae Hyoung Cho
Journal of Diabetes and its Complications.2015; 29(6): 776. CrossRef
Glycated Albumin Levels in Patients with Type 2 Diabetes Increase Relative to HbA1cwith Time
Hye-jin Yoon, Yong-ho Lee, Kwang Joon Kim, So Ra Kim, Eun Seok Kang, Bong-Soo Cha, Hyun Chul Lee, Byung-Wan Lee
BioMed Research International.2015; 2015: 1. CrossRef
Brief Review of Articles in 'Endocrinology and Metabolism' in 2013
Won-Young Lee
Endocrinology and Metabolism.2014; 29(3): 251. CrossRef
Inverse Association between Glycated Albumin and Insulin Secretory Function May Explain Higher Levels of Glycated Albumin in Subjects with Longer Duration of Diabetes
Yong-ho Lee, Mi Hyang Kown, Kwang Joon Kim, Eun Young Lee, Daham Kim, Byung-Wan Lee, Eun Seok Kang, Bong Soo Cha, Hyun Chul Lee, Marià Alemany
PLoS ONE.2014; 9(9): e108772. CrossRef
HbA1c Variability and Micro- and Macrovascular Complications of Diabetes
Hae Kyung Yang, Seung-Hwan Lee
The Journal of Korean Diabetes.2014; 15(4): 202. CrossRef
Letter: A1c Variability Can Predict Coronary Artery Disease in Patients with Type 2 Diabetes with Mean A1c Level Greater than 7 (Endocrinol Metab 2013;28:125-32, Eun Ju Lee et al.)
Hye Seung Jung
Endocrinology and Metabolism.2013; 28(4): 346. CrossRef

Study Design and Protocol for a Randomized Controlled Trial to Assess Long-Term Efficacy and Safety of a Triple Combination of Ezetimibe, Fenofibrate, and Moderate-Intensity Statin in Patients with Type 2 Diabetes and Modifiable Cardiovascular Risk Factors (ENSEMBLE): Nam Hoon Kim, Juneyoung Lee, Suk Chon, Jae Myung Yu, In-Kyung Jeong, Soo Lim, Won Jun Kim, Keeho Song, Ho Chan Cho, Hea Min Yu, Kyoung-Ah Kim, Sang Soo Kim, Soon Hee Lee, Chong Hwa Kim, Soo Heon Kwak, Yong‐ho Lee, Choon Hee Chung, Sihoon Lee, Heung Yong Jin, Jae Hyuk Lee, Gwanpyo Koh, Sang-Yong Kim, Jaetaek Kim, Ju Hee Lee, Tae Nyun Kim, Hyun Jeong Jeon, Ji Hyun Lee, Jae-Han Jeon, Hye Jin Yoo, Hee Kyung Kim, Hyeong-Kyu Park, Il Seong Nam-Goong, Seongbin Hong, Chul Woo Ahn, Ji Hee Yu, Jong Heon Park, Keun-Gyu Park, Chan Ho Park, Kyong Hye Joung, Ohk-Hyun Ryu, Keun Yong Park, Eun-Gyoung Hong, Bong-Soo Cha, Kyu Chang Won, Yoon-Sok Chung, Sin Gon Kim; Received April 1, 2024 Accepted June 12, 2024 Published online August 22, 2024; DOI: https://doi.org/10.3803/EnM.2024.1995 [Epub ahead of print]

513 View
78 Download

Abstract PDF PubReader ePub: Background
Atherogenic dyslipidemia, which is frequently associated with type 2 diabetes (T2D) and insulin resistance, contributes to the development of vascular complications. Statin therapy is the primary approach to dyslipidemia management in T2D, however, the role of non-statin therapy remains unclear. Ezetimibe reduces cholesterol burden by inhibiting intestinal cholesterol absorption. Fibrates lower triglyceride levels and increase high-density lipoprotein cholesterol (HDL-C) levels via peroxisome proliferator- activated receptor alpha agonism. Therefore, when combined, these drugs effectively lower non-HDL-C levels. Despite this, few clinical trials have specifically targeted non-HDL-C, and the efficacy of triple combination therapies, including statins, ezetimibe, and fibrates, has yet to be determined.
Methods
This is a multicenter, prospective, randomized, open-label, active-comparator controlled trial involving 3,958 eligible participants with T2D, cardiovascular risk factors, and elevated non-HDL-C (≥100 mg/dL). Participants, already on moderate-intensity statins, will be randomly assigned to either Ezefeno (ezetimibe/fenofibrate) addition or statin dose-escalation. The primary end point is the development of a composite of major adverse cardiovascular and diabetic microvascular events over 48 months.
Conclusion
This trial aims to assess whether combining statins, ezetimibe, and fenofibrate is as effective as, or possibly superior to, statin monotherapy intensification in lowering cardiovascular and microvascular disease risk for patients with T2D. This could propose a novel therapeutic approach for managing dyslipidemia in T2D.

Author index